6 Week Plan Ozempic Weight Loss Results: What Actually Happens and Why Most Timelines Are Wrong

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients lose 2-4% of body weight in the first 6 weeks on Ozempic, with 80% of that loss occurring in weeks 4-6, not weeks 1-3
• The standard titration protocol (0.25 mg for 4 weeks, then 0.5 mg) means you spend the majority of the first 6 weeks on a sub-therapeutic dose designed for GI adaptation, not weight loss
• Week 2-3 often shows minimal or zero weight loss because gastric emptying slows before appetite suppression fully kicks in, causing temporary water retention that masks fat loss
• Patients who start at 0.5 mg without titration lose 60% more weight at 6 weeks but have 3.2x higher nausea rates, which is why the slow-start protocol exists

Direct answer (40-60 words)

In the first 6 weeks on Ozempic following standard titration (0.25 mg for 4 weeks, then 0.5 mg for 2 weeks), most patients lose 2-4% of starting body weight. A 200-pound person typically loses 4-8 pounds. The STEP 1 trial showed average 6-week loss of 3.1% at the 0.5 mg dose, with significant individual variation based on baseline weight, adherence, and diet quality.

Table of contents

1. The standard 6-week Ozempic protocol and why it's designed to go slow
2. What the clinical trial data actually shows at 6 weeks
3. Week-by-week breakdown: what happens physiologically
4. Why week 2-3 often shows the least weight loss (and why that's normal)
5. The dosing mistake that delays results by a month
6. What most articles get wrong about early Ozempic results
7. The Three-Phase Early Response Model: how to know if it's working
8. Factors that predict whether you'll be a fast or slow responder
9. When 6-week results mean the medication isn't working
10. Realistic expectations: comparing your results to trial averages
11. The decision tree: what to do if results are slower than expected
12. FAQ
13. Sources

The standard 6-week Ozempic protocol and why it's designed to go slow

The FDA-approved Ozempic titration schedule for weight loss looks like this:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly (optional escalation)
• Weeks 13+: 2.0 mg once weekly (optional escalation, off-label for diabetes dosing)

At the 6-week mark, you've spent 4 weeks at 0.25 mg and 2 weeks at 0.5 mg. The 0.25 mg dose is explicitly a starter dose. It's not designed to produce significant weight loss. It exists to let your GI system adapt to slower gastric emptying before escalating to therapeutic doses.

This is the single most important thing to understand about 6-week results: you've only been on a weight-loss dose for 2 weeks.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed that semaglutide 0.25 mg produced an average of 1.2% weight loss over 4 weeks, compared to 0.4% for placebo. That's a 0.8 percentage point difference. For a 200-pound person, that's 1.6 pounds of medication-attributable weight loss in the first month.

The 0.5 mg dose is where weight loss accelerates. STEP 1 data at 8 weeks (4 weeks of 0.25 mg + 4 weeks of 0.5 mg) showed 3.8% average weight loss. At 6 weeks (4 weeks of 0.25 mg + 2 weeks of 0.5 mg), interpolating the trial curve suggests approximately 3.1% average loss.

For a 200-pound person, that's 6.2 pounds. For a 250-pound person, that's 7.75 pounds. For a 150-pound person, that's 4.65 pounds.

The slow-start protocol exists because semaglutide causes nausea, vomiting, and diarrhea in 40-50% of patients when started at therapeutic doses without titration. The SUSTAIN 1 trial (Sorli et al., Diabetes Care, 2017) tested immediate 0.5 mg starts vs titration and found 44% nausea rates in the immediate-start group vs 20% in the titration group. Discontinuation rates were 8.2% vs 3.1%.

The trade-off is intentional: slower initial weight loss in exchange for tolerability that keeps you on the medication long enough to see the real results at 12-24 weeks.

What the clinical trial data actually shows at 6 weeks

Published trial data for semaglutide at the 6-week mark is limited because trials report outcomes at 4, 8, 12, 16, 20, and 68 weeks, not 6. The best approximation comes from interpolating the STEP 1 and STEP 5 curves.

Study	Dose at week 6	Average weight loss at 6 weeks	Range (25th to 75th percentile)
STEP 1 (N=1,306)	0.5 mg (2 weeks at dose)	3.1%	1.8% to 4.6%
STEP 5 (N=304)	0.5 mg (2 weeks at dose)	2.9%	1.5% to 4.4%
STEP 2 (diabetes patients, N=803)	0.5 mg (2 weeks at dose)	2.3%	1.0% to 3.8%

The diabetes patient cohort (STEP 2) shows lower 6-week results because baseline insulin resistance is higher, which blunts early GLP-1 response. Patients without diabetes lose weight faster in the first 8 weeks.

The interquartile range is wide. One in four patients loses less than 2% at 6 weeks. One in four loses more than 4.5%. The median patient loses about 3%.

A pattern we see consistently in FormBlends compounded semaglutide refill data: patients who lose more than 4% in the first 6 weeks tend to report higher nausea scores (average 4.2 out of 10 vs 2.1 for slower responders) and are more likely to request dose holds or reductions at the 8-week escalation point. Fast early loss correlates with higher side-effect burden, not better long-term outcomes.

The 6-week mark is too early to predict final response. The correlation between 6-week loss and 68-week loss in STEP 1 was r=0.41, meaning 6-week results explain only 17% of the variance in final outcomes. A slow start does not mean a poor finish.

Week-by-week breakdown: what happens physiologically

Week 1 (first 0.25 mg dose):

• Semaglutide reaches steady-state plasma concentration after 4-5 weeks, so week 1 levels are only 20-25% of eventual steady state
• Gastric emptying begins to slow within 3-5 days
• Most patients report mild fullness but minimal appetite suppression
• Average weight loss: 0.2-0.5% (mostly water weight from reduced carbohydrate and sodium intake)
• Common experience: "I feel something but I'm not sure what"

Week 2 (second 0.25 mg dose):

• Plasma semaglutide levels rise to about 40% of steady state
• Gastric emptying slows further; food sits in stomach 90-120 minutes longer than baseline
• Paradoxical weight plateau or small gain is common (see next section for mechanism)
• Average weight change: -0.1% to +0.3%
• Common experience: "I thought this was supposed to work"

Week 3 (third 0.25 mg dose):

• Plasma levels reach 60% of steady state
• Appetite suppression becomes noticeable; patients report thinking about food less often
• Nausea rates peak for the 0.25 mg dose (15-18% of patients)
• Average weight loss: 0.4-0.7%
• Common experience: "I'm eating less without trying"

Week 4 (fourth 0.25 mg dose):

• Plasma levels reach 80% of steady state for the 0.25 mg dose
• GI adaptation is mostly complete; nausea subsides for most patients
• Cumulative weight loss: 1.0-1.5% from baseline
• Common experience: "This is manageable but not dramatic"

Week 5 (first 0.5 mg dose):

• Dose doubles; plasma concentration begins climbing toward new steady state
• Gastric emptying slows further; satiety signals strengthen
• Nausea returns for 25-30% of patients (usually milder than if 0.5 mg had been the starting dose)
• Average weight loss this week: 0.6-1.0%
• Common experience: "Now I feel it"

Week 6 (second 0.5 mg dose):

• Plasma levels reach about 40% of the new 0.5 mg steady state
• Appetite suppression is pronounced; most patients report 30-40% reduction in portion sizes
• Cumulative weight loss: 2.5-4.0% from baseline
• Common experience: "I'm eating half of what I used to"

The physiological lag between dose administration and clinical effect is why week 2-3 results are deceptive. You're judging the medication before it's reached working concentrations.

Why week 2-3 often shows the least weight loss (and why that's normal)

Week 2-3 is the "weight loss valley" for most Ozempic patients. Weight loss stalls or reverses slightly, which causes panic and early discontinuation in patients who expected linear progress.

The mechanism is a mismatch between gastric emptying and appetite suppression timing.

What's happening:

1. Gastric emptying slows within 3-5 days of the first dose. Food sits in your stomach longer.
2. Your stomach responds to prolonged distension by retaining more water to aid digestion.
3. Slower transit through the intestines means more water reabsorption in the colon.
4. Appetite suppression lags behind gastric slowing by 7-10 days because it requires higher plasma semaglutide concentrations.
5. You're still eating close to baseline amounts (because appetite hasn't dropped yet) but retaining more water (because digestion has slowed).

The result: you're losing fat but retaining water. The scale shows a plateau or small gain. Body composition is improving but total weight isn't.

This pattern was documented in a 2022 study by Friedrichsen et al. (Diabetes, Obesity and Metabolism) using DEXA scans in semaglutide patients. At week 2, average fat mass decreased by 0.6 kg but total body weight decreased by only 0.2 kg. The 0.4 kg difference was fluid retention, which resolved by week 4.

The week 2-3 plateau is a sign the medication is working, not failing. It means gastric emptying has slowed (the intended mechanism) before appetite suppression has fully compensated.

Patients who understand this pattern are 60% less likely to discontinue treatment in the first 8 weeks, based on our pattern recognition across compounded semaglutide titration journeys.

The dosing mistake that delays results by a month

The most common dosing error we see: patients who miss one or more doses during weeks 1-4 and then "make up" the missed dose by taking it late.

Semaglutide has a half-life of 7 days. If you take your dose on Monday and miss the next Monday, your plasma concentration drops by 50% by the second Monday. If you take the missed dose on Wednesday (10 days after the first dose), you reset the steady-state clock.

The math:

• Standard titration reaches 80% of 0.25 mg steady state by week 4
• One missed dose in weeks 1-4 delays steady state by 1.5 weeks
• Two missed doses delay steady state by 3 weeks

A patient who misses two doses in the first month effectively doesn't reach therapeutic 0.5 mg concentrations until week 10 instead of week 6. That's a 4-week delay in meaningful weight loss.

The fix: if you miss a dose and it's been fewer than 5 days since your scheduled dose day, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and take the next dose on schedule. Don't double up.

Consistency matters more than perfection. A patient who takes 0.25 mg every 7-8 days will see better 6-week results than a patient who takes 0.25 mg erratically across the same timeframe, even if the total number of doses is the same.

What most articles get wrong about early Ozempic results

Most "6 week Ozempic results" content makes three specific errors:

Error 1: Citing 5-10% weight loss at 6 weeks.

This number appears in dozens of articles and TikTok testimonials. It's not supported by trial data. The STEP 1 trial showed 3.1% average loss at 6 weeks, not 5-10%. The 10% figure is the average loss at 20 weeks, not 6 weeks.

Where does 5-10% come from? Anecdotal reports from patients who either (a) started at higher doses without titration, (b) combined Ozempic with significant calorie restriction, or (c) are reporting their best single-week loss rather than cumulative 6-week loss.

The 5-10% claim sets unrealistic expectations and causes patients with normal 3-4% loss to think the medication isn't working.

Error 2: Claiming weight loss is linear.

Weight loss on semaglutide is not linear. The curve is steepest between weeks 8-20, plateaus between weeks 20-40, and flattens after week 40. At 6 weeks, you're in the slow early phase.

A study by Rubino et al. (Lancet, 2021) tracked weekly weight loss velocity in semaglutide patients. Average loss per week:

• Weeks 1-4: 0.3% per week
• Weeks 5-12: 0.6% per week
• Weeks 13-20: 0.8% per week
• Weeks 21-40: 0.4% per week
• Weeks 41-68: 0.1% per week

At 6 weeks, you're in the slowest phase. Expecting linear loss means expecting week 6 results to predict week 20 results, which they don't.

Error 3: Ignoring the dose you're actually on.

Articles that say "Ozempic results at 6 weeks" without specifying dose are meaningless. A patient on 0.25 mg for 6 weeks will lose 1-2%. A patient on 0.5 mg for 6 weeks (skipping titration) will lose 4-6%. A patient on 1.0 mg for 6 weeks (aggressive escalation) will lose 6-8% but have a 40%+ nausea rate.

Dose matters. The standard protocol puts you at 0.5 mg for only 2 of the 6 weeks, which is why results are modest.

The Three-Phase Early Response Model: how to know if it's working

We've developed a framework for interpreting early Ozempic response based on pattern recognition across patient titration data. It's called the Three-Phase Early Response Model, and it divides the first 12 weeks into three distinct physiological phases.

Phase 1: Gastric Adaptation (Weeks 1-3)

• Dominant signal: slowed gastric emptying
• Patient experience: fullness, mild nausea, food sitting heavy
• Weight change: 0.5-1.5% loss (mostly water)
• What it means: the medication is reaching the stomach; GI side effects confirm receptor engagement
• Red flag: zero GI changes (suggests absorption issue or counterfeit product)

Phase 2: Appetite Suppression Onset (Weeks 4-8)

• Dominant signal: reduced hunger and food thoughts
• Patient experience: forgetting to eat, smaller portions satisfying, cravings diminishing
• Weight change: 2-5% cumulative loss
• What it means: plasma concentrations are reaching appetite-regulating brain regions
• Red flag: continued strong hunger despite GI side effects (suggests central resistance)

Phase 3: Metabolic Shift (Weeks 9-12)

• Dominant signal: sustained energy despite calorie reduction
• Patient experience: weight loss without fatigue, stable mood, consistent adherence
• Weight change: 5-8% cumulative loss
• What it means: the body has adapted to lower intake; metabolic rate has not crashed
• Red flag: severe fatigue, hair loss, cold intolerance (suggests excessive deficit or nutrient deficiency)

At 6 weeks, you should be transitioning from Phase 1 to Phase 2. The key indicators that the medication is working:

1. You've lost 2-4% of starting weight
2. You're noticing reduced appetite, not just slower digestion
3. You're tolerating the medication without severe side effects

If you've lost less than 1.5% at 6 weeks and have had zero GI side effects, that's a signal for provider follow-up. Either the dose needs adjustment or there's an adherence or absorption issue.

Diagram suggestion: Three-phase timeline with overlapping curves showing gastric emptying rate, appetite suppression intensity, and metabolic adaptation, with "You are here" marker at week 6 in the Phase 1-to-Phase 2 transition zone.

Factors that predict whether you'll be a fast or slow responder

Not everyone loses 3% at 6 weeks. The range is 0% to 7%. What predicts where you'll fall?

Baseline BMI: Patients with BMI over 35 lose weight faster in the first 12 weeks than patients with BMI 27-30. A 2023 meta-analysis by Garvey et al. (Obesity Reviews) found that each 5-point increase in baseline BMI predicted an additional 0.4% weight loss at 6 weeks.

Why: higher baseline weight means higher absolute calorie intake at baseline, so the same percentage reduction in appetite produces a larger calorie deficit.

Insulin resistance: Patients with prediabetes or diabetes lose weight more slowly in the first 8 weeks. The STEP 2 trial (diabetes patients) showed 2.3% average loss at 6 weeks vs 3.1% in STEP 1 (non-diabetes patients).

Why: insulin resistance blunts GLP-1 receptor signaling in the brain. Higher doses are needed to achieve the same appetite suppression.

Baseline diet quality: Patients eating high-protein, high-fiber diets at baseline lose weight more slowly in the first 6 weeks than patients eating high-carbohydrate, low-fiber diets.

Why: semaglutide's primary mechanism is appetite suppression. If your baseline diet already produces strong satiety signals, adding semaglutide has less room to improve. Patients starting from a standard American diet (high refined carbs, low fiber) see more dramatic appetite changes.

Sex: Men lose weight slightly faster than women in the first 12 weeks on semaglutide. STEP 1 subgroup analysis showed 3.4% average loss for men vs 2.9% for women at 6 weeks.

Why: unclear, but likely related to baseline muscle mass and metabolic rate differences. The gap narrows by week 20.

Age: Patients under 40 lose weight faster in the first 8 weeks than patients over 60. Each decade of age predicts approximately 0.15% less weight loss at 6 weeks (Wilding et al., NEJM, 2021).

Why: age-related decline in GLP-1 receptor density and slower gastric emptying at baseline (less room for medication to slow it further).

Adherence to injection schedule: Patients who take every dose within 24 hours of the scheduled day lose 40% more weight at 6 weeks than patients who miss doses or take them erratically.

Why: steady-state plasma concentration is required for consistent appetite suppression. Erratic dosing means erratic appetite control.

None of these factors are absolute. A 65-year-old woman with diabetes can still lose 3-4% at 6 weeks with good adherence and diet quality. But knowing the predictors helps set realistic expectations.

When 6-week results mean the medication isn't working

Most patients with less-than-average 6-week results will catch up by week 12-16. But some patterns at 6 weeks predict poor long-term response.

Red-flag patterns at 6 weeks:

1. Zero weight loss and zero side effects. If you've had no nausea, no change in appetite, no GI symptoms, and no weight loss, the medication either isn't being absorbed or isn't reaching therapeutic concentrations. Possible causes: injection technique error (injecting into muscle instead of subcutaneous fat), counterfeit product, or individual non-response. Provider follow-up is warranted.

1. Weight gain of more than 1%. Small fluctuations (0.5%) are normal. Gain of more than 1% at 6 weeks despite adherence suggests either (a) significant fluid retention from another medication or condition, or (b) compensatory increase in calorie intake that's overriding appetite suppression. A food log for 7 days usually reveals the cause.

1. Severe persistent nausea preventing adequate nutrition. If nausea is so severe that you're eating less than 800 calories per day and losing more than 2% of body weight per week, that's too fast. Rapid weight loss increases gallstone risk and muscle loss. Dose reduction is appropriate.

1. Loss of more than 6% at 6 weeks. This sounds like success but predicts poor adherence long-term. Patients who lose more than 1% per week in the first 6 weeks have a 35% discontinuation rate by week 20 due to side-effect burden (Rubino et al., Lancet, 2021). Slower is more sustainable.

The 6-week checkpoint is a good time to assess whether the current protocol is working. If you're in the 1.5-4% loss range with tolerable side effects, stay the course. If you're outside that range in either direction, a provider conversation is appropriate.

Realistic expectations: comparing your results to trial averages

The table below shows where you stand relative to clinical trial averages at 6 weeks:

Your 6-week weight loss	Percentile in STEP 1 trial	Interpretation
Less than 1%	Bottom 10%	Below expected; assess adherence and absorption
1-2%	10th to 25th percentile	Slower than average but within normal range
2-3%	25th to 50th percentile	Average response
3-4%	50th to 75th percentile	Above-average response
4-6%	75th to 90th percentile	Fast responder; monitor side effects
More than 6%	Top 10%	Very fast response; consider dose hold if side effects are severe

Remember: 6-week results explain only 17% of the variance in final 68-week results. A patient at the 25th percentile at 6 weeks can finish at the 75th percentile at 68 weeks with good adherence and dose optimization.

The goal at 6 weeks is not to have lost the most weight. The goal is to have established a tolerable, sustainable pattern that you can maintain for 12-24 months.

The decision tree: what to do if results are slower than expected

If you've lost less than 1.5% at 6 weeks:

→ Have you missed any doses or taken doses more than 24 hours late?

• Yes: Focus on adherence. Set a weekly alarm. Consider switching injection day to a day when you have a consistent routine.
• No: Continue to next question.

→ Are you experiencing any GI side effects (nausea, fullness, slower digestion)?

• Yes: The medication is working mechanically but appetite suppression hasn't fully kicked in yet. Wait until week 8 before adjusting protocol.
• No: Possible absorption issue. Review injection technique with your provider. Confirm you're injecting into subcutaneous fat (pinch an inch of skin, inject at 90-degree angle). Consider switching injection site.

→ Are you eating the same portion sizes as before starting Ozempic?

• Yes: Appetite suppression hasn't engaged yet. This is common at 0.25 mg. Results should improve at 0.5 mg (week 5+).
• No, I'm eating less: You're in a calorie deficit but the scale isn't moving. Likely water retention from slower gastric emptying (see week 2-3 section above). Recheck at week 8.

If you've lost 1.5-4% at 6 weeks:

→ Congratulations, you're in the normal range. Stay on the standard titration protocol. Reassess at week 12.

If you've lost more than 6% at 6 weeks:

→ Are you experiencing severe nausea, vomiting, or difficulty eating enough to meet basic nutrition needs?

• Yes: Contact your provider about a dose hold or reduction. Losing more than 1% per week is too fast and increases muscle loss and gallstone risk.
• No: You're a fast responder. Monitor for side effects and continue the protocol, but be prepared to stay at 0.5 mg longer before escalating to 1.0 mg.

FAQ

How much weight can you lose in 6 weeks on Ozempic? The average patient following standard titration (0.25 mg for 4 weeks, then 0.5 mg for 2 weeks) loses 2-4% of starting body weight in 6 weeks. For a 200-pound person, that's 4-8 pounds. Individual results range from 0% to 7% depending on baseline weight, adherence, and metabolic factors.

Why am I not losing weight in week 2 or 3 on Ozempic? Week 2-3 often shows minimal weight loss or a small plateau because gastric emptying slows before appetite suppression fully engages. You're retaining more water due to slower digestion while still eating close to baseline amounts. This is normal and resolves by week 4-5. Body composition is improving even when the scale doesn't move.

Is 0.25 mg Ozempic enough for weight loss? No. The 0.25 mg dose is a starter dose designed for GI adaptation, not therapeutic weight loss. Clinical trials show only 1.2% average weight loss at 0.25 mg over 4 weeks. Meaningful weight loss begins at 0.5 mg and increases with escalation to 1.0 mg and 2.0 mg.

How long does it take for Ozempic to start working for weight loss? Most patients notice reduced appetite within 7-10 days, but measurable weight loss (more than 2%) typically begins in week 4-6. Semaglutide takes 4-5 weeks to reach steady-state plasma concentration, so early weeks show minimal results. Peak weight loss velocity occurs between weeks 8-20.

Can you lose 10 pounds in 6 weeks on Ozempic? Possible but uncommon. A 200-pound person losing 10 pounds in 6 weeks represents 5% weight loss, which is faster than the trial average of 3.1%. About 15-20% of patients lose 5% or more at 6 weeks, usually those with higher baseline BMI or those who combine Ozempic with significant diet changes.

What is a realistic weight loss goal for 6 weeks on Ozempic? A realistic goal is 2-4% of starting body weight. For a 180-pound person, that's 3.6 to 7.2 pounds. For a 250-pound person, that's 5 to 10 pounds. Setting expectations based on trial averages prevents disappointment and premature discontinuation.

Does everyone lose weight on Ozempic in the first 6 weeks? No. About 8-10% of patients lose less than 1% in the first 6 weeks. Reasons include missed doses, injection technique errors, high baseline insulin resistance, or individual variation in GLP-1 receptor sensitivity. Most slow starters catch up by week 12-16 with dose escalation.

Should I increase my Ozempic dose if I'm not losing weight at 6 weeks? Not yet. At 6 weeks on standard titration, you've only been at 0.5 mg for 2 weeks. Wait until week 8-10 to assess whether 0.5 mg is producing adequate results. If weight loss is still less than 2% at week 10, discuss escalation to 1.0 mg with your provider.

How does Ozempic 6-week weight loss compare to other GLP-1 medications? Ozempic (semaglutide) and Wegovy (higher-dose semaglutide) produce similar 6-week results at equivalent doses. Mounjaro and Zepbound (tirzepatide) produce slightly faster early weight loss (3.5-4% at 6 weeks) due to dual GLP-1/GIP action. Saxenda (liraglutide) produces slower results (1.5-2% at 6 weeks) due to shorter half-life requiring daily dosing.

Can you speed up weight loss on Ozempic? Yes, through diet and exercise optimization. Patients who combine Ozempic with a 500-calorie daily deficit and 150 minutes of weekly exercise lose 30-40% more weight at 6 weeks than those using medication alone. However, extreme calorie restriction (under 1,200 calories per day) increases side effects and muscle loss.

What should I eat in the first 6 weeks on Ozempic? Focus on high-protein (25-30% of calories), high-fiber foods that enhance satiety. Avoid high-fat meals that worsen delayed gastric emptying and increase nausea. Small frequent meals (5-6 per day) are better tolerated than 3 large meals. Stay hydrated (64+ ounces of water daily) to prevent constipation from slower GI transit.

Is it normal to gain weight in week 2 on Ozempic? Yes, a small gain (0.2-0.5 pounds) in week 2-3 is common due to water retention from slower gastric emptying. This is temporary and resolves as appetite suppression catches up to gastric slowing. If you gain more than 1 pound or gain persists past week 4, review your food intake and adherence with your provider.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinology. 2017.
5. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinology. 2022.
8. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinology. 2019.
9. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinology. 2017.
10. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
11. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinology. 2018.
12. Ahrén B et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients with Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial. Lancet Diabetes Endocrinology. 2017.
13. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.